<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058198</url>
  </required_header>
  <id_info>
    <org_study_id>81672476</org_study_id>
    <nct_id>NCT03058198</nct_id>
  </id_info>
  <brief_title>The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma</brief_title>
  <official_title>The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma and Its Correlation to EGFRvIII</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The epidermal growth factor receptor variant Ⅲ(EGFR vⅢ) is commonly detected in high-grade
      gliomas, which is also an important epitope in EGFR-targeted therapies and correlated to poor
      prognosis. However, detection of this mutant usually needs resected tumor samples. For biopsy
      samples, test results may not represent the EGFR vⅢ status of the whole tumor tissues because
      of the heterogeneity of tumor. It is also not applicable for patients who are not suitable
      for surgical procedure due to the tumor location or patients' general conditions. Because of
      the importance of the epidermal growth factor receptor (EGFR) signal pathway in oncogenesis,
      maintenance, and progression of high grade glioma, there has been an intense effort to
      develop noninvasive molecular imaging approach for the selection and monitoring of
      EGFR-targeted therapies.

      Based on investigators' previous study, investigators plan to perform PET scanning on the
      participants with high grade gliomas after the injection of the second generation of EGFR
      tracer ,89Zr-ABT806, which can be specifically binded to EGFR vⅢ . After fusing the PET and
      MRI images, investigators precisely obtain the tissue from the&quot;hot-spot&quot; on the PET image
      through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status will be detected by
      molecular methods to analyze the correlation with the 89Zr-ABT806 PET image qualitatively and
      quantitatively. Investigators' final goal is to detect EGFR vⅢ by noninvasive molecular
      imaging procedure for the clinical outcome prediction and the selection of EGFR-targeted
      therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The sensitivity and specificity of 89Zr-ABT806 PET</measure>
    <time_frame>4 years</time_frame>
    <description>After fusing the 89Zr-ABT806 PET and MRI images, investigators precisely obtained the tissue from the&quot;hot-spot&quot; on the PET image through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status will be analyzed by molecular methods. The sensitivity and specificity of 89Zr-ABT806 PET will be measured with statistic methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The overall survival time of participants</measure>
    <time_frame>4 years</time_frame>
    <description>regular follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The progression-free survival time of participants</measure>
    <time_frame>4 year</time_frame>
    <description>regular follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between EGFRvIII mutation and prognosis of participants</measure>
    <time_frame>4 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>High Grade Glioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We plan to perform PET scanning on the patients with high grade gliomas after the injection of the second generation of EGFR tracer ,89Zr-ABT806（1-2mCi）, which can be specifically binded to EGFR vⅢ . After fusing the PET and MRI images, we precisely obtained the tissue from the&quot;hot-spot&quot; on the PET image through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status was detected by Sanger sequencing to analyze the correlation with the 89Zr-ABT806 PET image qualitatively and quantitatively. The final goal was to detect EGFR vⅢ by noninvasive molecular imaging procedure for the clinical outcome prediction and the selection of EGFR-targeted therapies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>89Zr-ABT806 PET</intervention_name>
    <description>Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.</description>
    <arm_group_label>High Grade Glioma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical manifestations and imaging examination (CT, MRI, et al) are in accordance
             with high grade glioma

          2. No PET/CT scanning contraindications

          3. No MRI scanning contraindications

          4. Patients older than 18 years old

          5. ECOG score between 0 to 2

          6. Patients with sufficient bone marrow, kidney and liver function reserve.

          7. All patients gave written informed consent.

        Exclusion Criteria:

          1. Patient who has received immune therapy, radiation therapy, chemotherapy, hormone
             drugs, biological products or other clinical trials within 14 days.

          2. Patient who has received EGFR monoclonal antibody therapy within 4 weeks.

          3. Patients who has not fully recovered form the past drug toxicity reaction (CTCAE in
             grade 2 or above).

          4. Patient who has received major surgery within 7 days.

          5. Patients with allergies to immunoglobulin.

          6. Breastfeeding women.

          7. pregnant women

          8. Patients with severe clinical condition.

          9. Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dongxiao Zhuang, Professor</last_name>
    <phone>+86-21-52888771</phone>
    <email>ernestzdx@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huashan hospital, Fudan university</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangfu Zhou, Professor</last_name>
      <phone>+86-21-52887200</phone>
      <email>lfzhouc@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Nijiati Kudulaiti, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dongxiao Zhuang, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhemin Huang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chengjun Yao, M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tainming Qiu, M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junfeng Lu, M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huiwei Zhang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhengwei Zhang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yihui Guan, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jingsong Wu, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhifeng Shi, M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jie Zhang, M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fangyuan Gong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhengda Yv, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9.</citation>
    <PMID>1557402</PMID>
  </reference>
  <reference>
    <citation>Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991 Apr 15;51(8):2164-72.</citation>
    <PMID>2009534</PMID>
  </reference>
  <reference>
    <citation>Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 1984 Feb;44(2):753-60.</citation>
    <PMID>6318976</PMID>
  </reference>
  <reference>
    <citation>Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8602-6.</citation>
    <PMID>2236070</PMID>
  </reference>
  <reference>
    <citation>Yamazaki H, Fukui Y, Ueyama Y, Tamaoki N, Kawamoto T, Taniguchi S, Shibuya M. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol. 1988 Apr;8(4):1816-20.</citation>
    <PMID>3380099</PMID>
  </reference>
  <reference>
    <citation>Malden LT, Novak U, Kaye AH, Burgess AW. Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res. 1988 May 15;48(10):2711-4.</citation>
    <PMID>2834047</PMID>
  </reference>
  <reference>
    <citation>Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13.</citation>
    <PMID>1584765</PMID>
  </reference>
  <reference>
    <citation>Nagane M, Coufal F, Lin H, Bögler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996 Nov 1;56(21):5079-86.</citation>
    <PMID>8895767</PMID>
  </reference>
  <reference>
    <citation>Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 1995 Oct;6(10):1251-9.</citation>
    <PMID>8845302</PMID>
  </reference>
  <reference>
    <citation>Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31.</citation>
    <PMID>8052651</PMID>
  </reference>
  <reference>
    <citation>Pedersen MW, Tkach V, Pedersen N, Berezin V, Poulsen HS. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer. 2004 Feb 20;108(5):643-53.</citation>
    <PMID>14696090</PMID>
  </reference>
  <reference>
    <citation>Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res. 2004 Oct 1;10(19):6732-43.</citation>
    <PMID>15475464</PMID>
  </reference>
  <reference>
    <citation>Lammering G, Valerie K, Lin PS, Hewit TH, Schmidt-Ullrich RK. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol. 2004 Sep;72(3):267-73.</citation>
    <PMID>15450724</PMID>
  </reference>
  <reference>
    <citation>Feldkamp MM, Lala P, Lau N, Roncari L, Guha A. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery. 1999 Dec;45(6):1442-53.</citation>
    <PMID>10598712</PMID>
  </reference>
  <reference>
    <citation>Emrich JG, Brady LW, Quang TS, Class R, Miyamoto C, Black P, Rodeck U. Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol. 2002 Dec;25(6):541-6.</citation>
    <PMID>12477994</PMID>
  </reference>
  <reference>
    <citation>Li G, Wong AJ. EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Rev Vaccines. 2008 Sep;7(7):977-85. doi: 10.1586/14760584.7.7.977. Review.</citation>
    <PMID>18767947</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Dongxiao Zhuang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>PET</keyword>
  <keyword>EGFR vIII</keyword>
  <keyword>Multimodal neuronavigation</keyword>
  <keyword>Molecular pathology</keyword>
  <keyword>PET-CT</keyword>
  <keyword>Neuronavigation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

